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Science Center at Houston, Houston, TX, USAA B S T R A C TObjectives: Most economic evaluations of chemotherapies for ovarian
cancer patients have used hypothetical cohorts or randomized control
trials, but evidence integrating real-world survival, cost, and utility
data is limited. Methods: A propensity score–matched cohort of 6856
elderly (Z65 years) ovarian cancer patients diagnosed from 1991 to
2005 from the Surveillance, Epidemiology, and End Results-
Medicare data cohort were included. Treatment regimens (i.e., no
chemotherapy, platinum-based only, platinum plus taxane, and
other nonplatinum) were identiﬁed in the 6 months postdiagnosis.
Patients were followed until death or end of study (December 2006).
Effectiveness was measured in quality-adjusted life-years (QALYs),
and total health care costs were measured by using a payer’s
perspective (2009 US dollars). Methodological and statistical uncer-
tainties were accounted by including alternative scenarios (for
utility values) and net monetary beneﬁt approach. Incremental
cost-effectiveness ratios (ICERs) were calculated, and stratiﬁed
analyses were performed by tumor stages and age groups. Results:see front matter Copyright & 2014, International S
r Inc.
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ondence to: David R. Lairson, School of Public Hea
ive, RAS E-307, Houston, TX.On comparing the platinum-based group versus no chemotherapy,
we found that the ICER was $30,073/QALY and $58,151/QALY for
early- and late-stage disease, respectively, while other nonplatinum
and platinum plus taxane groups were dominated (less effective
and more costly). Similar results were found across alternative
scenarios and age groups. For patients 85 years or older, platinum
plus taxane, however, was not dominated by the platinum-based
group, with an ICER of $133,892/QALY. Conclusions: Following
elderly ovarian cancer patients over a lifetime using real-world
longitudinal data and adjusting for quality of life, we found that
treatment with platinum-based regimen was the most cost-effective
treatment alternative.
Keywords: chemotherapy, cost-effectiveness, cost-utility, ovarian
cancer.
Copyright & 2014, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
The primary treatment for women with early-stage ovarian
cancer is surgical resection/tumor debulking followed by sys-
temic chemotherapy. For patients with stage IA or IB and grade I
ovarian cancer, observation is recommended after surgery
because of the high cure rate for these patients with surgery
alone. Controversy remains regarding the potential beneﬁt of
adjuvant chemotherapy for patients with stage IA and grade II
tumors; the National Institutes of Health consensus expert panel
has reported that either observation or chemotherapy is an
appropriate recommendation [1–3]. For patients with higher
grade tumors and/or more advanced stages of disease, systemic
chemotherapy is recommended [1–3]. Platinum and taxane com-
bination is the recommended primary therapy for cancer stages
IC to IV, while single agents may be administered depending on
the platinum sensitivity of the tumor [2]. We recently reported
chemotherapy effectiveness results from a national study of12,181 patients aged 65 years and older diagnosed with stages I
to IV ovarian cancer and treated from 1991 to 2005 [4]. Platinum
and taxane combination therapies and platinum-based therapies
without taxane yielded an increased survival, including a sig-
niﬁcant dose-response effect among patients with late-stage
cancer. For patients with early-stage ovarian cancer, platinum
and taxane combination therapy was more effective than other
chemotherapy treatments. Combination therapy, however, had
higher toxicity, which was consistent with clinical trial ﬁndings.
Survival was poor among patients initially diagnosed with late-
stage cancer, regardless of chemotherapy treatment.
While survival is of primary importance, there are concerns
about decreasing effectiveness of chemotherapy in an aging
population, the effects of toxicity on quality of life, and the
cost-effectiveness of alternative treatments. While clinical trials
have shown that the efﬁcacy of adjuvant chemotherapy for
breast cancer decreases with age [5–8], currently no evidence
shows decreasing efﬁcacy of chemotherapy with age for ovarianociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 3 4 – 4 2 35cancer [9–14]. There are model-based cost-effectiveness studies
[15–19] of alternative ovarian cancer chemotherapy regimens, but
none was on a national population of community-based patients
and providers, incorporating quality of life, or investigating cost-
effectiveness of treatments as patients age. Furthermore, pre-
vious ovarian cancer cost-effectiveness studies have focused on
individual drugs, administration route, and treatment frequency
[15–19]. Most studies derive effectiveness from clinical trials with
a limited time horizon [18,20–22]. Empirical studies included
patients with a mean age of 60 years and a maximum age of 85
years [15,19,23,24]. In randomized clinical trials, the combination
of cisplatin and paclitaxel has been shown to be a cost-effective
ﬁrst-line therapy [15,19,24,25]. Among platinum-sensitive recur-
rent patients, carboplatin and paclitaxel therapy was cost-
effective as compared with carboplatin alone or other platinum-
based therapies [18,21]. For example, Havrilesky et al. [18] found
an incremental cost-effectiveness ratio (ICER) of $15,564 per
progression-free life-year for carboplatin and paclitaxel versus
an ICER of $278,388 for carboplatin and gemcitabine.
We used a large national Surveillance, Epidemiology, and End
Results (SEER)-Medicare data set to examine whether common
chemotherapy regimens for women with ovarian cancer re-
mained effective as women age, and which chemotherapy
regimens were cost-effective and offered the highest quality-
adjusted survival. The study complements randomized clinical
trials and modeling studies of ovarian cancer and further informs
decision makers who are concerned about the economic and
clinical consequences of cancer treatment in an aging population.
The methodology and novelty of the approach to real-world
population-based patient data can be applied to answer similar
questions for patients with other tumors and serve as a reference
to other investigators.Methods
Data Source, Population, and Chemotherapy Regimens
A retrospective cohort study was conducted by using the SEER
and Medicare linked database. Additional information on SEER
and SEER-Medicare linkage is described in Supplemental
Materials found at http://dx.doi.org/10.1016/j.jval.2013.11.007.
Women diagnosed with ovarian cancer as the ﬁrst primary tumor
without other primary tumors at age 65 years or older from
January 1, 1991, to December 31, 2005 [4], were considered for the
study. A total of 12,181 women with American Joint Committee
on Cancer stages I to IV or unknown stage at diagnosis were
identiﬁed from 16 SEER areas. Patients with American Joint
Committee on Cancer stage IA or IB were included in the study
because some received chemotherapy and the National Institutes
of Health consensus expert panel felt that either observation or
chemotherapy is appropriate [1–3]. Patients were considered to
have received chemotherapy if associated codes (see
Supplemental Materials) were identiﬁed within 180 days after
diagnosis in Medicare claims. Chemotherapy regimens were
deﬁned by using HCPCS codes J9045, J9060, J9062, and J9263 for
platinum-based drugs and J9170 and J9265 for taxanes. Propensity
scores (conditional probability) were computed for the receipt of
platinum-based chemotherapy as compared with the receipt of
other nonplatinum chemotherapy or no chemotherapy, while
adjusting for age, ethnicity, marital status, tumor stage, grade,
size, number of positive lymph nodes, comorbidity, surgery,
radiation therapy, socioeconomic status, and year of diagnosis.
A one-to-one match was performed on the basis of the above-
obtained propensity scores by using the 5-1 digit validated
matching algorithm [26]. The matched sample comprised 6856
ovarian cancer patients (3428 each in platinum-basedchemotherapy and nonplatinum/no chemotherapy group).
Patients were then hierarchically grouped into four categories:
no chemotherapy, other nonplatinum chemotherapy, only
platinum-based chemotherapy, and platinum plus taxane che-
motherapy. Platinum plus taxane categorization required both
platinum and taxane claims within 141 days, accommodating six
cycles of 3 weeks each and an additional 15-day grace period.
Plots of propensity score distribution across all four groups of
patients showed considerable overlap, suggesting them to be
comparable (see Fig. 1 in Supplemental Materials found at http://
dx.doi.org/10.1016/j.jval.2013.11.007.
Effectiveness
Effectiveness was measured as quality-adjusted life-years
(QALYs), obtained by adjusting overall survival with phase-,
stage-, and adverse event–speciﬁc utilities. Overall survival bene-
ﬁts were calculated by following patients from the start of treat-
ment to death or end of study (December 31, 2006). Survival time
after treatment initiation was distributed into initial, continuing,
and terminal phases (see Fig. 2 in Supplemental Materials found
at http://dx.doi.org/10.1016/j.jval.2013.11.007). The initial and ter-
minal phases were the ﬁrst and last 6 months of life, respectively,
while the continuing phase was the time between initial and
terminal phases. Patients alive at the end of the study were not
assigned terminal phase time. Patients surviving less than 6
months were assigned only to the terminal phase, and patients
surviving less than a year had the last 6 months assigned to the
terminal phase and the remainder to the initial phase [27].
Utility weights were obtained from the existing literature and
were assigned to each phase [28,29]. Base-case and alternative
(best-case and worst-case) scenario utility weights are listed in
Table 1. During the initial phase, patients categorized in the “no
chemotherapy” group were assigned a diagnosis stage–speciﬁc
utility (“early ovarian cancer” and “advanced ovarian cancer”).
Patients who received some chemotherapy during the initial
phase were given a utility weight associated with “chemother-
apy/grade 1/2 toxicity.” Adverse events identiﬁed from inpatient
Medicare claims were considered grade 3/4 adverse events and
were assigned a utility weight associated with “chemotherapy/
grade 3/4 toxicity.” Adverse events identiﬁed by using International
Classiﬁcation of Diseases, Ninth Revision, Clinical Modiﬁcation diag-
nosis codes included alopecia, nausea/vomiting, fatigue, neutro-
penia, myalgia/pain, stomatitis, and peripheral neuropathy [30].
In the continuing phase, patients were assigned the average of
utilities associated with “remission” and “progression.” A “termi-
nal cancer” utility was applied to the terminal phase. For the time
between diagnosis and start of the initial phase, stage-speciﬁc
utilities were applied. Finally, individual phase-speciﬁc QALYs
were obtained by multiplying the time spent in that phase with
the associated utility weight. Total QALYs for each patient were
obtained by summing all phase-speciﬁc QALYs and were dis-
counted by 3% annually [31].
Cost Analysis
Health care costs were estimated from a payer perspective, using
the amount Medicare paid for each claim. Because cancer treat-
ments may affect the overall morbidity, total health care costs
were calculated including inpatient services, outpatient visits
and procedures, physician fees, skilled nursing facility, hospice,
and costs for devices and medical equipment from the start of
treatment until death or end of study. Costs were aggregated by
phase by using criteria similar to that for distributing QALYs. Cost
data were aggregated over a 16-year period (1991–2006) and from
various geographical locations, necessitating adjustment for
inﬂation and the cost of doing business, respectively [32]. Brown
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Fig. 1 – Cost-effectiveness acceptability curves for ovarian cancer patients—base case.
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 3 4 – 4 236et al. [32] carried out these adjustments by using the Prospective
Payment System Hospital Price index and Geographic Adjust-
ment Factor for Medicare Part A claims (inpatient, hospice, and
home health), whereas for Part B claims (outpatient, physician,
and device and medical equipment), Medicare Economic Index
and Geographic Practice Cost Index are used. These price adjust-
ers were obtained by special request from the National Cancer
Institute and Information Management Services, Inc. Price
adjusters speciﬁc to metropolitan area or county were matched
with each patient’s county at diagnosis. This match was per-
formed by using the registry code variable and FederalTable 1 – Utility weights* assigned to various disease ph
Treatment phases Base-case scen
Initial phase
No chemotherapy, early stage 0.93
No chemotherapy, late stage 0.50
Chemotherapy, no grade 3/4 adverse event† 0.67
Chemotherapy, grade 3/4 adverse event‡ 0.50
Continuing phase 0.63
Terminal phase 0.16
* Utility weights were obtained from the literature [27,28].
† Occurrence of a grade 3/4 adverse event was checked at intervals of 3
‡ ■■■Information Processing Standard county code from the SEER
data. A 3% annual discount rate was applied, and costs are
presented in 2009 US dollars [31].Cost-Effectiveness Analysis
Cost-effectiveness was estimated by computing ICERs and using
the net monetary beneﬁt (NMB) approach. ICERs were calculated
by the ratio of difference in average total health care costs of
chemotherapy regimens divided by the difference in average
QALYs; that is, ICER ¼ Δ Cost/Δ Effectiveness [33]. We arrangedases in base-case and alternative scenarios.
ario Best-case scenario Worst-case scenario
0.93 0.93
0.50 0.50
0.67 0.50
0.95 0.30
0.25 0.03
months in the initial phase.
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 3 4 – 4 2 37the regimens in ascending order of their average cost before
calculating the ICERs for each successive regimen.
The NMB approach incorporates changes in costs and effec-
tiveness into a linear regression [33]. NMB is deﬁned as λbij  cij,
where λ is the willingness-to-pay threshold, bij is the effective-
ness, and cij is the cost of treatment j for patient i [34,35]. The
NMB multivariate regression model was [34–36] as follows:
λbijcij¼ β0þ β1 other nonplatinum chemotherapyþ β2 platinum-based chemotherapyþ
β3 platinum and taxane chemotherapyþ β4 ageþu
For this study, λ values varied from $30,000 to $180,000. The
statistical signiﬁcance (95% conﬁdence interval and P value) for
the NMB and uncertainty around the willingness-to-pay thresh-
old value was determined by computing cost-effectiveness
acceptability curves. ICERs and NMB regressions were calculated
for base-case and alternative scenarios, and ICERs were esti-
mated for chemotherapy regimens in each age group.
Sensitivity Analysis
Uncertainty in utility measurement was assessed for alternative
utility weight allocation scenarios. Under the best case, all
patients receiving chemotherapy in the initial phase received a
utility weight for “chemotherapy/grade 1/2 toxicity,” in the con-
tinuing phase for “remission,” and in the terminal phase an
upper range of terminal cancer utility (Table 1). Alternatively, for
the worst case, patients were assigned a utility weight for
“chemotherapy/grade 3/4 toxicity” in the initial phase (when
receiving chemotherapy), 0.30 in the continuing phase, and in
the terminal phase for “end-stage ovarian cancer” (Table 1).Results
Of the 6856 matched ovarian cancer patients, 33% (n ¼ 2255)
received platinum and taxane therapy, 31% (n ¼ 2093) received no
chemotherapy, 19% (n ¼ 1335) received other nonplatinum
chemotherapy, and 17% (n ¼ 1173) received only platinum-
based chemotherapy (Table 2). Patients receiving chemotherapy
were similar with regard to age and race (Table 2). Patients notTable 2 – Characteristics of ovarian cancer patients from
Characteristics No
chemotherapy
Othe
ch
Total N (row %) ¼ 6856 (100) 2093 (31)
Age (y), median (range) 77 (65–99)
Age (y), n (%)
65–69 350 (16.7)
70–74 424 (20.3)
75–79 514 (24.6)
80–84 508 (24.3)
85þ 297 (14.2)
Race/ethnicity, n (%)
Caucasians 1838 (87.8)
African Americans 112 (5.4)
Others 143 (6.8)
Tumor American Joint Committee on
Cancer stage, n (%)
I–AB 209 (10)
I–C 128 (6.1)
II 175 (8.4)
III 615 (29.4)
IV 738 (35.3)
Unknown 228 (10.9)receiving chemotherapy were older. Patients diagnosed with
early stage (I or II) tumor were less likely to receive chemotherapy
than were those with more advanced stages of disease (III, IV, or
unstaged).
Total health care costs per month by disease phase of care
and treatment type are shown in Table 3. A “U”-shaped cost
curve was observed, with higher costs during the initial phase,
declining costs in the continuing phase, and rising costs again in
the terminal phase. Health care costs for advanced stage disease
were higher in initial and continuing phases than in the early
stage. Terminal-phase costs (except “no chemotherapy” group)
were relatively similar for both early- and late-stage patients.
Across all the disease phases in early-stage patients, the “other
nonplatinum chemotherapy” group incurred the highest cost
($126,376), followed by the “platinum and taxane” group
($122,631) (Table 4). Similarly, for late-stage diagnosed patients,
the “platinum and taxane” group had the highest costs ($149,669),
followed by the “other nonplatinum chemotherapy” group
($140,947).
The frequency of patients who encountered either a grade 1/2
or a grade 3/4 adverse event is summarized in the Supplemental
Materials found at http://dx.doi.org/10.1016/j.jval.2013.11.007.
During the initial phase, a grade 3/4 adverse event was observed
among 26.4%, 18.9%, and 17.7% of the patients in the “other
nonplatinum chemotherapy,” “platinum and taxane,” and
“platinum-based chemotherapy” groups, respectively. Table 4
summarizes mean life-years and QALYs for all treatment groups
by cancer stage at diagnosis. For early- and late-stage patients,
those in the “platinum-based chemotherapy” group had the lon-
gest mean life-years and QALYs (Table 4). For early-stage patients,
mean life-years and QALYs ranged from 3.5 to 5.2 and 2.3 to 3.3
years, respectively. For late-stage patients, mean life-years and
QALYs ranged from 1.0 to 2.6 and 0.5 to 1.5 years, respectively.
ICERs and NMB results are also reported in Table 4. The “other
nonplatinum chemotherapy” and “platinum and taxane” treat-
ment groups were dominated by the “platinum-based chemo-
therapy” group after arranging chemotherapy regimens in
ascending order of average health care costs and comparing
mean life-years as well as QALYs of the previous chemotherapy
alternative. This result was similar for patients diagnosed at boththe matched cohort.
r nonplatinum
emotherapy
Platinum-based
chemotherapy
Platinum and
taxane
1335 (19) 1173 (17) 2255 (33)
73 (65–98) 74 (65–94) 76 (65–94)
399 (29.9) 298 (25.4) 458 (20.3)
415 (31.1) 298 (25.4) 536 (23.8)
342 (25.6) 281 (24.0) 584 (25.9)
140 (10.5) 186 (15.9) 478 (21.2)
39 (2.9) 110 (9.4) 199 (8.8)
1158 (86.7) 1051 (89.6) 1939 (86)
88 (6.6) 54 (4.6) 158 (7.0)
89 (6.7) 68 (5.8) 158 (7.0)
18 (1.4) 53 (4.5) 174 (7.7)
53 (4.0) 51 (4.4) 121 (5.4)
76 (5.7) 91 (7.8) 156 (6.9)
571 (42.8) 384 (32.7) 825 (36.6)
553 (41.4) 487 (41.5) 797 (35.3)
64 (4.8) 107 (9.1) 182 (8.1)
Table 3 – Total health care costs per month in
different disease phases by chemotherapy type and
cancer stage.
Chemotherapy
regimens
Total health care costs per month
($), mean  SD
Early-stage
ovarian cancer
Late-stage
ovarian cancer
Initial phase*,† (6 mo
after diagnosis)
N ¼ 1,174 N ¼ 3,934
No chemotherapy 7,881  22,511 11,181  33,378
Other nonplatinum
chemotherapy
10,215  18,134 14,912  23,323
Platinum-based
chemotherapy
7,360  4,389 10,297  33,408
Platinum and taxane 10,156  6,598 12,337  10,112
Continuing phase*,†
(between initial and
terminal phases)
N ¼ 1,092 N ¼ 3,139
No chemotherapy 1,326  2,449 1,885  3,232
Other nonplatinum
chemotherapy
1,718  2,380 3,326  3,465
Platinum-based
chemotherapy
1,351  1,620 2,969  4,694
Platinum and taxane 1,737  2,678 3,748  3,560
Terminal phase*,†
(6 mo before death)
N ¼ 650 N ¼ 4,984
No chemotherapy 9,887  15,177 18,339  25,816
Other nonplatinum
chemotherapy
10,406  13,917 12,800  15,256
Platinum-based
chemotherapy
6,384  5,473 7,497  7,059
Platinum and taxane 8,824  9,538 9,854  9,280
* Costs incurred in the last 6 mo of life will be assigned to the
terminal phase. If patients lived for less than or equal to 6 mo,
then all costs were assigned to the terminal phase. Similarly, costs
incurred in the ﬁrst 6 mo after diagnosis were assigned to the
initial phase and if the patient lived for more than 6 mo but less
than or equal to 12 mo, then the costs remaining after 6 mo of the
terminal phase were assigned to the initial phase. If the patient
lived more than a year, then the time between the initial phase
and the terminal phase was assigned as the continuing phase.
† Patients who had an initial/continuing/terminal phase of care.
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 3 4 – 4 238early and late stages. Per each QALY gained, the ICER for
“platinum-based chemotherapy” group as compared with “no
chemotherapy” group among early-stage patients was $30,073,
while for late-stage patients, it was $58,151 (Table 4). Accounting
only for life-years gained, these ICERs were observed to be
$18,318 and $35,867 per each life-year gained, respectively. At a
willingness-to-pay (λ) threshold of $100,000, adjusting for age and
considering “no chemotherapy” as baseline, the NMB for “plati-
num-based chemotherapy” was $66,077 for early-stage patients
and $39,457 for late-stage patients. For the other two treatment
groups, the NMB was negative at a willingness-to-pay threshold
of $100,000, but conﬁdence intervals spanned a wide range of
uncertainty (Table 4). Cost-effectiveness acceptability curves
(Fig. 1) show the uncertainty around these threshold values. For
early-stage patients, “platinum-based chemotherapy” is cost-
effective at lower willingness-to-pay thresholds ($50,000) and
other chemotherapies become cost-effective only at higher
willingness-to-pay thresholds (4$180,000). Similarly, “platinum-based chemotherapy” remains cost-effective for advanced stage
patients at lower willingness-to-pay thresholds ($65,000), while
other chemotherapy regimens become cost-effective at higher
willingness-to-pay thresholds ($125,000).
ICERs for alternative scenarios are shown in the Supplemental
Materials found at http://dx.doi.org/10.1016/j.jval.2013.11.007.
Similar to the base case, “platinum-based chemotherapy” domi-
nated both “other nonplatinum chemotherapy” and “platinum
and taxane” regimens in best-case and worst-case scenarios.
Among patients younger than 80 years, ICERs for “platinum-
based chemotherapy” ranged from $53,394 to $84,841, dominat-
ing other treatment regimens (Table 5). For the age group of 80 to
84 years, the ICER for “other nonplatinum chemotherapy” was
found to be $156,062, showing extended dominance due to
“platinum-based chemotherapy” at an ICER of $7,183. For the
85 years or older age group, “platinum and taxane” was more
effective but more expensive than “platinum-based chemother-
apy.” Moreover, “platinum-based chemotherapy” (ICER $148,301)
was observed to have extended dominance with respect to
“platinum and taxane” (ICER $133,892).Discussion
This cost-utility analysis of commonly used chemotherapy regi-
mens for a national cohort of women diagnosed with ovarian
cancer by tumor stage and age at diagnosis yields results gen-
erally consistent with previous randomized trials and treatment
guidelines. The “other nonplatinum chemotherapy” and “plati-
num and taxane” treatment groups were dominated (less effec-
tive and more costly) by the “platinum-based chemotherapy”
group when comparing mean life-years and QALYs. The results
were similar for patients diagnosed at early stage and more
advanced stages. This result remains robust across all age groups
except for those 85 years and older, in whom “platinum and
taxane” is the most cost-effective option. The cost per QALY,
when comparing “platinum-based chemotherapy” with “no che-
motherapy,” generally rose with age, but reached only about
$150,000 for the oldest age group.
While there are no directly comparable studies examining the
cost-effectiveness of chemotherapy for ovarian cancer among
elderly patients in the community, previous economic research
provides some perspective on the results. Studies conducted in
the late 1990s and early 2000s focused on younger patients and
were often based on modeling of data from randomized con-
trolled trials of selected patients and providers. By using data
from the Gynecologic Oncology Group trial and associated ﬁnan-
cial costs, McGuire et al. [25] found that a combination of cisplatin
and paclitaxel had an ICER of $19,820 and $21,222 (1996 US
dollars) as compared with cisplatin and cyclophosphamide for
inpatient- and outpatient-related treatment, respectively [25].
Costs in this study, however, were restricted to the end of
primary cancer therapy. Havrilesky et al. [18] applied a Markov
model using data from published randomized trials and costs
from the U.S. Center for Medicare & Medicaid services to estimate
the cost-effectiveness of treatments for platinum-sensitive ovar-
ian cancer. The paclitaxel and carboplatin combination had an
ICER of $15,564 per progression-free life-year gained, while the
gemcitabine and carboplatin combination had an ICER of
$278,388 per progression-free life-year gained (2006 US dollars)
[18]. Similar methods were used to examine the cost-
effectiveness of concurrent docetaxel and carboplatin combina-
tion versus sequential docetaxel and carboplatin [16]. Concurrent
treatment was cost-effective, with a threshold of $50,000 per
QALY, and the ﬁndings remained robust in sensitivity analyses.
From a French university perspective, Limat et al. [37] estimated
an ICER of $13,827 per QALY for the paclitaxel-cisplatin regimen
Table 4 – Cost-effectiveness of chemotherapies by cancer stage for life-years and QALYs.
Effectiveness Early-stage ovarian cancer Late-stage ovarian cancer
Life-years, mean  SD QALY, mean  SD Life-years, mean  SD QALY, mean  SD
No chemotherapy 3.5  2.8 2.3  1.9 1.0  1.6 0.5  1.0
Other nonplatinum chemotherapy 4.6  3.6 2.9 2.5 2.2  2.5 1.3  1.6
Platinum-based chemotherapy 5.2  3.8 3.3  2.6 2.6  2.6 1.5  1.7
Platinum and taxane 3.8  2.4 2.4  1.6 2.3  1.9 1.3  1.3
Total health care cost ($) Mean  SD Mean  SD
No chemotherapy 83,430  96,637 63,804  70,907
Other nonplatinum chemotherapy 126,376  107,807 140,947  109,382
Platinum-based chemotherapy 115,364  76,563 120,829  85,008
Platinum and taxane 122,631  94,015 149,669  109,675
ICER ($)* Per life-year gained Per QALY gained Per life-year gained Per QALY gained
No chemotherapy – – – –
Other nonplatinum chemotherapy Dominated by platinum- based chemotherapy Dominated by platinum-based chemotherapy
Platinum-based chemotherapy 18,318 30,073 35,867 58,151
Platinum and taxane Dominated by platinum-based chemotherapy Dominated by platinum- based chemotherapy
Net monetary beneﬁt† Per patient (life-years),
$ (CI)
Per patient (QALY),
$ (CI)
Per patient (life-years),
$ (CI)
Per patient (QALY),
$ (CI)
Other nonplatinum chemotherapy vs. no chemotherapy 34,554 (18,682 to 87,790) 959 (39,062 to 37,143) 40,547 (25,638–55,456) 567 (11,211 to 10,076)
Platinum-based chemotherapy vs. no chemotherapy 130,452 (82,960–177,944) 66,077 (32,085– 100,068) 96,310 (80,795–111,826) 39,457 (28,380– 50,534)
Platinum and taxane vs. no chemotherapy 22,308 (58,861 to 14,245) 35,286 (61,448 to 9,123) 38,933 (25,856–52,009) 7,252 (16,587 to 2083)
CI, conﬁdence interval; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-years.
* ICER calculated by arranging in ascending order of total health care cost.
† Beta estimates from the net beneﬁt regression adjusted for age with λ ¼ 100,000.
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Table 5 – QALYs, costs, and ICER calculated by age groups and chemotherapy type.
Age group Total health care
costs ($), mean  SD
QALY,
mean  SD
ICER per
QALY ($)
Life-years,
mean  SD
ICER per life-year
gained ($)
65–69 y
No chemotherapy 79,152  104,052 1.4  1.8 – 2.3  2.6 –
Other
nonplatinum
chemotherapy
159,094  107,637 1.8  2.0 Dominated by platinum-
based chemotherapy
3.1  3.0 Dominated by platinum-
based chemotherapy
Platinum-based
chemotherapy
137,020  96,415 2.3  2.5 63,918 3.8  3.5 38,563
Platinum and
taxane
159,173  123,208 1.9  1.7 Dominated by platinum-
based chemotherapy
3.1  2.5 Dominated by platinum-
based chemotherapy
70–74 y
No chemotherapy 76,253  83,097 1.1  1.7 – 1.9  2.5 –
Other
nonplatinum
chemotherapy
145,544  125,183 1.5  1.8 Dominated by platinum-
based chemotherapy
2.6  2.8 Dominated by platinum-
based chemotherapy
Platinum-based
chemotherapy
122,598  78,818 2.0  2.2 53,394 3.4  3.2 31,526
Platinum and
taxane
153,817  107,434 1.7  1.5 Dominated by platinum-
based chemotherapy
2.8  2.2 Dominated by platinum-
based chemotherapy
75–79 y
No chemotherapy 69,996  77,523 0.9  1.5 – 1.5  2.2 –
Other
nonplatinum
chemotherapy
131,352  97,471 1.3  1.7 Dominated by platinum-
based chemotherapy
2.3  2.5 Dominated by platinum-
based chemotherapy
Platinum-based
chemotherapy
121,693  80,334 1.5  1.7 84,841 2.6  2.5 48,026
Platinum and
taxane
145,261  107,965 1.5  1.3 Dominated by platinum-
based chemotherapy
2.5  2.0 Dominated by platinum-
based chemotherapy
80–84 y
No chemotherapy 59,632  64,033 0.6  1.2 – 1.1  1.7 –
Other
nonplatinum
chemotherapy
102,003  79,108 0.9  1.2 156,062† 1.6  1.9 91,473#
Platinum-based
chemotherapy
106,808  68,525 1.5  1.7 7,183 2.7  2.5 4,490
Platinum and
taxane
131,056  91,357 1.2  1.1 Dominated by platinum-
based chemotherapy
2.1  1.7 Dominated by platinum-
based chemotherapy
85 y and older
No chemotherapy 58,198  54,085 0.6  1.1 – 1.2  1.6 –
Other
nonplatinum
chemotherapy
75,397  66,871 0.5  1.1 Dominated by no
chemotherapy
1.0  1.7 Dominated by no
chemotherapy
Platinum-based
chemotherapy
83,988  77,598 0.8  0.9 148,301† 1.5  1.4 73,510
Platinum and
taxane
112,995  90,179 1.0  1.0 133,892 1.8  1.6 100,037
ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year.
* ICER calculated by arranging in ascending order of total health care cost.
† Extended dominance.
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US dollars). Costs, however, were collected only until the com-
pletion of ﬁrst-line chemotherapy [37]. Cohn et al. [38] modeled
the use of paclitaxel and carboplatin compared with carboplatin
plus bevacizumab and found an ICER of $479,712 per progression-
free life-year saved (2009 US dollars). Economic evaluations have
also compared chemotherapy regimens administered intrave-
nously (IV) versus intraperitoneally (IP). A decision modeling
study by Havrilesky et al. [17] comparing IV cisplatin/carboplatin
and paclitaxel with IP cisplatin and paclitaxel found that the
IP regimen had an ICER of $32,053 per QALY over the life span(2006 US dollars). A similar study by Bristow et al. [39] comparing
a combination of IV and IP paclitaxel þ IP cisplatin with IV pacli-
taxel and carboplatin estimated an ICER of $60,976 per QALY
(2006 US dollars).
There are some limitations to the current study. First, obser-
vational claims-based studies are subject to selection bias. To
minimize this bias, we applied propensity score matching based
on observable sociodemographic and clinical characteristics.
While the comparison groups were well balanced on these fac-
tors, differences in unobservable factors may exist. Future studies
should search for an appropriate instrumental variable that
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 3 4 – 4 2 41controls for possible selection effects due to unmeasured varia-
bles. Second, because SEER-Medicare claims data do not contain
direct measures of quality of life/utilities, utility measures were
obtained from the literature as proxies for quality of life and
identiﬁed grade 3/4 adverse events from inpatient claims during
the initial phase. When quality of life was adjusted in the model,
we observed increased ICERs, but the rank order of the ICERs for
each chemotherapy regimen was maintained. Third, cases in this
study from SEER areas may not be representative of cancer care
patterns in the country. For example, our study excluded those
with health maintenance organization membership because of
their incomplete claims in Medicare, but health maintenance
organization physicians may have ﬁnancial incentives for
reduced medical care utilization compared with regular fee-for-
service Medicare [40]. With the growth of Medicare Advantage
plans, it will become increasingly important to capture health
care utilization and cost data on their members, for more
generalizable ﬁndings on the cost-effectiveness of cancer treat-
ments [41]. Our study does not measure indirect cost of cancer
treatment incurred by patients and their caregivers, and thus
falls short of a societal evaluation. Lost productivity and market
earnings should not be a large factor due to the age of the
Medicare population, although family members may experience
work loss and there are friction costs imposed on employers. The
payer perspective in the analysis is highly relevant to Medicare
program decision makers [42].
Given resource scarcity, the aging population, and toxicity of
many cancer treatments, it is important to consider the cost-
effectiveness and cost-utility of alternative treatment strategies in
the clinical and community settings. The available large national
SEER-Medicare data set combined with economic and statistical
methods provided an important complement to randomized
clinical trials and decision-analytic modeling studies for assessing
the “real-world” performance of outcomes of cancer treatment
and prevention strategies. Furthermore, the methods applied in
the current study can be reﬁned and applied to other cancer
treatment issues to develop policy-relevant information for
increasing the beneﬁts of treatment with limited resources for
cancer treatments at any given period of time. Additional research
is needed to improve the comparability of patient groups with
techniques for controlling for unmeasured differences that may
inﬂuence cost and outcome and to develop more phase-speciﬁc
quality-of-life indicators that capture the effects of treatment
stratiﬁed by disease stage.Acknowledgments
We acknowledge the efforts of the National Cancer Institute,
Center for Medicare & Medicaid Services, Information Manage-
ment Services, Inc., and the SEER Program tumor registries in the
creation of this database. The interpretation and reporting of
these data are the sole responsibilities of the authors. We are also
very grateful to Dr. Keith Burau, who recently passed away
because of his illness and complications, for his superior SAS
data programming and data management services in this project.
Source of ﬁnancial support: This study was supported by a
grant from the Agency for Healthcare Research and Quality (grant
no. R01-HS018956).Supplemental Materials
Supplemental material accompanying this article can be found in
the online version as a hyperlink at http://dx.doi.org/10.1016/j.
jval.2013.11.007 or, if a hard copy of article, at www.valueinhealth
journal.com/issues (select volume, issue, and article).R E F E R E N C E S[1] NIH consensus conference. Ovarian cancer. Screening, treatment, and
follow-up. NIH Consensus Development Panel on Ovarian Cancer.
JAMA 1995;273:491–7.
[2] National Comprehensive Cancer Network. The Complete Library of
NCCN Oncology Practice Guidelines. Version 2000.
[3] Abraham J, Allegra CJ. Bethesda Handbook of Clinical Oncology.
Philadelphia, PA: Lippincott Williams & Wilkins, 2001.
[4] Du XL, Parikh RC, Lairson DR, et al. Comparative effectiveness of
platinum-based chemotherapy versus taxane and other regimens for
ovarian cancer. Med Oncol 2013;30:1–14.
[5] Cole BF, Gelber RD, Gelber S, et al. Polychemotherapy for early breast
cancer: an overview of the randomised clinical trials with quality-
adjusted survival analysis. Lancet 2001;358:277–86.
[6] Polychemotherapy for early breast cancer: an overview of the
randomised trials. Early Breast Cancer Trialists’ Collaborative Group.
Lancet 1998;352:930–42.
[7] Early Breast Cancer Trialists’ Collaborative Group. Effects of
chemotherapy and hormonal therapy for early breast cancer on
recurrence and 15-year survival: an overview of the randomised trials.
Lancet 2005;365(9472):1687–717.
[8] Early Breast Cancer Trialists’ Collaborative Group, Clarke M, Coates AS,
et al. Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer:
patient-level meta-analysis of randomised trials. Lancet 2008;371:29–40.
[9] Kyrgiou M, Salanti G, Pavlidis N, et al. Survival beneﬁts with diverse
chemotherapy regimens for ovarian cancer: meta-analysis of multiple
treatments. J Natl Cancer Inst 2006;98:1655–63.
[10] Higgins RV, Naumann RW, Gardner J, Hall JB. Is age a barrier to the
aggressive treatment of ovarian cancer with paclitaxel and
carboplatin? Gynecol Oncol 1999;75:464–7.
[11] Ceccaroni M, D’Agostino G, Ferrandina G, et al. Gynecological
malignancies in elderly patients: is age 70 a limit to standard-dose
chemotherapy? An Italian retrospective toxicity multicentric study.
Gynecol Oncol 2002;85:445–50.
[12] Villella JA, Chaudhry T, Pearl ML, et al. Comparison of tolerance of
combination carboplatin and paclitaxel chemotherapy by age in
women with ovarian cancer. Gynecol Oncol 2002;86:316–22.
[13] Freyer G, Geay J, Touzet S, et al. Comprehensive geriatric assessment
predicts tolerance to chemotherapy and survival in elderly patients
with advanced ovarian carcinoma: a GINECO study. Ann Oncol
2005;16:1795–800.
[14] Zola P, Ferrero A. Is carboplatin–paclitaxel combination the standard
treatment of elderly ovarian cancer patients? Ann Oncol 2007;18:213–4.
[15] Ortega A, Dranitsaris G, Sturgeon J, et al. Cost–utility analysis of
paclitaxel in combination with cisplatin for patients with advanced
ovarian cancer. Gynecol Oncol 1997;66:454–63.
[16] Havrilesky LJ, Pokrzywinski R, Revicki D, et al. Cost‐effectiveness of
combination versus sequential docetaxel and carboplatin for the
treatment of platinum‐sensitive, recurrent ovarian cancer. Cancer
2012;118:386–91.
[17] Havrilesky LJ, Secord AA, Darcy KM, et al. Cost effectiveness of
intraperitoneal compared with intravenous chemotherapy for women
with optimally resected stage III ovarian cancer: a Gynecologic
Oncology Group study. J Clin Oncol 2008;26:4144–50.
[18] Havrilesky LJ, Secord AA, Kulasingam S, Myers E. Management of
platinum-sensitive recurrent ovarian cancer: a cost-effectiveness
analysis. Gynecol Oncol 2007;107:211–8.
[19] Berger K, Fischer T, Szucs T. Cost-effectiveness analysis of paclitaxel
and cisplatin versus cyclophosphamide and cisplatin as ﬁrst-line
therapy in advanced ovarian cancer. A European perspective. Eur J
Cancer 1998;34(12):1894–901.
[20] Rocconi RP, Case AS, Straughn JM, et al. Role of chemotherapy for
patients with recurrent platinum‐resistant advanced epithelial ovarian
cancer. Cancer 2006;107:536–43.
[21] Case AS, Rocconi RP, Partridge EE, Straughn JM Jr. A cost-effectiveness
analysis of chemotherapy for patients with recurrent platinum-
sensitive epithelial ovarian cancer. Gynecol Oncol 2007;105:223–7.
[22] Dalton HJ, Yu X, Hu L, et al. An economic analysis of dose dense weekly
paclitaxel plus carboplatin versus every-3-week paclitaxel plus
carboplatin in the treatment of advanced ovarian cancer. Gynecol
Oncol 2012;124:199–204.
[23] Limat S, Woronoff-Lemsi M, Menat C, et al. From randomised clinical
trials to clinical practice. Pharmacoeconomics 2004;22:633–41.
[24] Neymark N, Gorlia T, Adriaenssen I, et al. Cost effectiveness of
paclitaxel/cisplatin compared with cyclophosphamide/cisplatin in the
treatment of advanced ovarian cancer in Belgium. Pharmacoeconomics
2002;20:485–97.
[25] McGuire W, Neugut AI, Arikian S, et al. Analysis of the cost-
effectiveness of paclitaxel as alternative combination therapy for
advanced ovarian cancer. J Clin Oncol 1997;15:640–5.
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 3 4 – 4 242[26] Reducing bias in a propensity score matched-pair sample using greedy
matching techniques. In: Proceedings of the Twenty-sixth Annual SAS
Users group international conference; 2001; SAS Institute, Inc.
[27] Sail KR, Franzini L, Lairson DR, Du XL. Clinical and economic outcomes
associated with adjuvant chemotherapy in elderly patients with early
stage operable breast cancer. Value Health 2012;15:72–80.
[28] Havrilesky LJ, Broadwater G, Davis DM, et al. Determination of quality
of life-related utilities for health states relevant to ovarian cancer
diagnosis and treatment. Gynecol Oncol 2009;113:216–20.
[29] Earle C, Chapman R, Baker C, et al. Systematic overview of cost-utility
assessments in oncology. J Clin Oncol 2000;18:3302–17.
[30] Du XL, Osborne C, Goodwin JS. Population-based assessment of
hospitalizations for toxicity from chemotherapy in older women with
breast cancer. J Clin Oncol 2002;20:4636–42.
[31] Gray AM, Clarke PM, Wolstenholme JL, Wordsworth S. Applied Methods
of Cost-Effectiveness Analysis in Healthcare. Oxford: Oxford University
Press, 2010.
[32] Brown ML, Riley GF, Schussler N, Etzioni R. Estimating health care costs
related to cancer treatment from SEER-Medicare data. Med Care
2002;40: IV-104–117.
[33] Drummond MF, Sculpher MJ, Torrance GW. Methods for the Economic
Evaluation of Health Care Programs. Oxford: Oxford University Press,
2005.
[34] Mitra N, Indurkhya A. A propensity score approach to estimating the
cost-effectiveness of medical therapies from observational data. Health
Econ 2005;14:805–15.[35] Hoch JS, Rockx MA, Krahn AD. Using the net beneﬁt regression
framework to construct cost-effectiveness acceptability curves: an
example using data from a trial of external loop recorders versus Holter
monitoring for ambulatory monitoring of “community acquired”
syncope. BMC Health Serv Res 2006;6:68.
[36] Indurkhya A, Mitra N, Schrag D. Using propensity scores to estimate the
cost-effectiveness of medical therapies. Stat Med 2005;25(9):1561–76.
[37] Limat S, Woronoff-Lemsi M, Menat C, et al. From randomised clinical
trials to clinical practice. Pharmacoeconomics 2004;22:633–41.
[38] Cohn DE, Kim KH, Resnick KE, et al. At what cost does a potential
survival advantage of bevacizumab make sense for the primary
treatment of ovarian cancer? A cost-effectiveness analysis. J Clin Oncol
2011;29:1247–51.
[39] Bristow RE, Santillan A, Salani R, et al. Intraperitoneal cisplatin and
paclitaxel versus intravenous carboplatin and paclitaxel chemotherapy
for stage III ovarian cancer: a cost-effectiveness analysis. Gynecol
Oncol 2007;106:476–81.
[40] Miller RH, Luft HS. HMO plan performance update: an analysis of the
literature, 1997–2001. Health Aff 2002;21:63–86.
[41] Landon BE, Zaslavsky AM, Saunders RC, et al. Analysis Of Medicare
Advantage HMOs Compared With Traditional Medicare Shows
Lower Use Of Many Services During 2003-09. Health Aff (Millwood)
2012;31(12):2609–17.
[42] Warren JL, Klabunde CN, Schrag D, et al. Overview of the SEER-
Medicare data: content, research applications, and generalizability to
the United States elderly population. Med Care 2002;40: IV-3–18.
